This week in industry includes trials on ponesimod for relapsing multiple sclerosis, the Accordion Pill® for Parkinson’s and cannabidiol oral solution for seizures.
Browsing: Epilepsy and seizure
A promising new study could provide an early warning system to enable people with epilepsy to know when they are at risk of having a seizure.
Researchers have recently found that the brains of children with severe epilepsy can be compensated by rewiring regions of the visual cortex after surgery.
A Phase III study has shown that cannabidiol can reduce seizures by almost half in children with Dravet syndrome, a rare type of severe epilepsy.
The Epilepsy Society is calling for the UK government to regulate flashing images online. This will help to safeguard individuals with photosensitive epilepsy.
Researchers have developed a ‘pacemaker for the brain’, which can monitor and stimulate electric currents, potentially leading to novel treatments in individuals with neurological diseases.
This week we look at a new migraine medicine, a rescheduling of cannabidiol for epilepsy and a successful trial for neuromyelitis optica spectrum disorder.
GW Pharmaceuticals announced the approval of EPIDIOLEX® (cannabidiol) oral solution as the first plant-derived cannabinoid prescription medication.
Hannah Cock provides insight into the current data, controversies and pipelines for the use of cannabis-derived therapeutics in epilepsy.